1,940 results on '"Shepherd, Frances A."'
Search Results
152. Concurrent Chemoradiation With or Without Durvalumab in Elderly Patients With Unresectable Stage III NSCLC: Safety and Efficacy
153. Prognostic and Predictive Effect of TP53 Mutations in Patients with Non–Small Cell Lung Cancer from Adjuvant Cisplatin–Based Therapy Randomized Trials: A LACE-Bio Pooled Analysis
154. Pooled Analysis of the Prognostic and Predictive Value of KRAS Mutation Status and Mutation Subtype in Patients with Non–Small Cell Lung Cancer Treated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
155. A Multicenter, Phase 2 Study of Vascular Endothelial Growth Factor Trap (Aflibercept) in Platinum- and Erlotinib-Resistant Adenocarcinoma of the Lung
156. Lung cancer screening using low-dose computed tomography in at-risk individuals: The Toronto experience
157. Phase II Study of Accelerated Hypofractionated Three-Dimensional Conformal Radiotherapy for Stage T1-3 N0 M0 Non–Small Cell Lung Cancer: NCIC CTG BR.25
158. EGFR Tyrosine Kinase Inhibitor Monotherapy Should Remain the Standard First-Line Treatment in Advanced EGFR-Mutant NSCLC
159. A Phase I/II Study of GTI-2040 Plus Docetaxel as Second-Line Treatment in Advanced Non-small Cell Lung Cancer: A Study of the PMH Phase II Consortium
160. The IASLC Lung Cancer Staging Project: Proposals Regarding the Relevance of TNM in the Pathologic Staging of Small Cell Lung Cancer in the Forthcoming (Seventh) Edition of the TNM Classification for Lung Cancer
161. Central Nervous System Pseudoprogression in a Patient Treated with PD-1 Checkpoint Inhibitor
162. PTPRF Expression as a Potential Prognostic/Predictive Marker for Treatment with Erlotinib in Non–Small-Cell Lung Cancer
163. Cabazitaxel Versus Topotecan in Patients with Small-Cell Lung Cancer with Progressive Disease During or After First-Line Platinum-Based Chemotherapy
164. Inhibiting MDM2-p53 Interaction Suppresses Tumor Growth in Patient-Derived Non–Small Cell Lung Cancer Xenograft Models
165. Diffuse Hemorrhagic Brain Metastases in an ALK Fusion Positive Patient on Crizotinib
166. Prevention and Management of Bone Metastases in Lung Cancer: A Review
167. Acceptance of pain: A study in patients with advanced cancer
168. Understanding Prognostic Gene Expression Signatures in Lung Cancer
169. Molecular predictive and prognostic markers in non-small-cell lung cancer
170. Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial
171. A clinical investigation of inhibitory effect of panobinostat on CYP2D6 substrate in patients with advanced cancer
172. Individualized therapy in the adjuvant setting for non-small cell lung cancer (NSCLC)
173. Treatment Strategies for KRAS Mutated Non-small Cell Lung Cancer
174. Treatment patterns and outcomes of patients with advanced pleural mesothelioma at an academic referral centre
175. Cutting Edge: Nucleocapsid Vaccine Elicits Spike-Independent SARS-CoV-2 Protective Immunity
176. Abstract 563: cfDNA-based analysis of minimal residual disease and T-cell receptor clonality as predictors of relapse in stage 3 NSCLC treated with chemoradiotherapy and durvalumab
177. The effect of prior cancer on non‐small cell lung cancer trial eligibility
178. Durability of CNS disease control in NSCLC patients with brain metastases treated with immune checkpoint inhibitors plus cranial radiotherapy
179. PP01.10 Real-World Outcomes of Patients with Advanced EGFR-Mutated NSCLC in Canada Using AI-Extracted Data
180. Differential Role of Estrogen Receptor Beta in Early Versus Metastatic Non-small Cell Lung Cancer
181. A Clinical Prognostic Index for Patients Treated with Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21
182. Tissue Heterogeneity of EGFR Mutation in Lung Adenocarcinoma
183. Second-Line Treatment of Advanced Non-small Cell Lung Cancer
184. Cooperative Group Portfolio in Locally Advanced Non–Small-Cell Lung Cancer: Are We Making Progress?
185. Cooperative Group Research Efforts in Lung Cancer: Focus on Early-Stage Non–Small-Cell Lung Cancer
186. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial
187. Resident preparedness in discussing prognosis in patients with advanced lung cancer
188. NCIC CTG IND.190 Phase I Trial of Dalotuzumab (MK-0646) in Combination with Cisplatin and Etoposide in Extensive-Stage Small-Cell Lung Cancer
189. Elderly patients with unresectable stage 3 NSCLC treated with definitive chemoradiation with or without durvalumab: Safety and outcomes.
190. The value of defining molecular resistance in patients with progressive EGFR and ALK-driven lung cancer in a public system.
191. Impact of KRAS mutational variant on response to immunotherapy in metastatic NSCLC.
192. Sequencing of systemic therapies in advanced NSCLC with MET exon 14 skipping mutation: A multicenter experience.
193. Preliminary results of BEAVER: An investigator-initiated phase II study of binimetinib and encorafenib for the treatment of advanced solid tumors with non-V600E BRAF mutations (mts).
194. Nucleocapsid vaccine elicits spike-independent SARS-CoV-2 protective immunity
195. Gene expression--based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study
196. The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals Regarding the Clinical Staging of Small Cell Lung Cancer in the Forthcoming (Seventh) Edition of the Tumor, Node, Metastasis Classification for Lung Cancer
197. Does Intensive Follow-up Alter Outcome in Patients with Advanced Lung Cancer?
198. Chemotherapy for Relapsed Small Cell Lung Cancer: A Systematic Review and Practice Guideline
199. A drug discovery platform to identify compounds that inhibit EGFR triple mutants
200. Protein-altering germline mutations implicate novel genes related to lung cancer development
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.